Trials / Completed
CompletedNCT01291667
Study for HER2-Overexpressed MBC Patients Treated by Cipterbin® Plus vinorelbinE
A Phase III Randomized Study for HER2-Overexpressed Metastatic Breast Cancer Patients Treated by Trastuzumab( Cipterbin®) Plus vinorelbinE Simultaneously or Sequencely
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 330 (estimated)
- Sponsor
- Shanghai CP Guojian Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Breast cancer is the most common malignant disease and the most frequent causes of cancer mortality in females worldwide. The situation is same as the world in China. Trastuzumab has been proved valuable treatment for HER2-positive breast cancer patients. Cipterbin® is developing by Shanghai CP Guojian Pharmaceutical Co.Ltd.Now we carried on the phase III trial in order to prove Cipterbin® 's efficacy and safety.
Conditions
Timeline
- Start date
- 2009-05-01
- First posted
- 2011-02-08
- Last updated
- 2011-02-08
Source: ClinicalTrials.gov record NCT01291667. Inclusion in this directory is not an endorsement.